NFE2L2 and head and neck squamous cell carcinoma: A slightly refined, 10-gene KEAP1/NRF2/CUL3 signature applied to the same dataset produced a similarly striking difference in overall survival and also identified that cisplatin resistant HNSCC tumors adopt an NRF2-active program to improve suvival and proliferative capacity 51.